These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2103 related items for PubMed ID: 17070169

  • 1. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 2. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW, SPORTIF Investigators.
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [Abstract] [Full Text] [Related]

  • 3. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 4. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006 Apr 24; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 5. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ, Frison L, Weaver D, Wilcox RG, Bylock A, Emanuelsson H, Held P, Oldgren J.
    Am Heart J; 2008 Feb 24; 155(2):382-7. PubMed ID: 18215612
    [Abstract] [Full Text] [Related]

  • 6. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators.
    Am Heart J; 2003 Sep 24; 146(3):431-8. PubMed ID: 12947359
    [Abstract] [Full Text] [Related]

  • 7. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY.
    Pathophysiol Haemost Thromb; 2005 Sep 24; 34 Suppl 1():25-30. PubMed ID: 15812201
    [Abstract] [Full Text] [Related]

  • 8. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb 26; 156(4):409-16. PubMed ID: 8607726
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB, Halperin JL.
    Semin Vasc Med; 2005 Aug 26; 5(3):285-92. PubMed ID: 16123916
    [Abstract] [Full Text] [Related]

  • 11. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC, Albers GW.
    Stroke; 2007 Mar 26; 38(3):874-80. PubMed ID: 17255547
    [Abstract] [Full Text] [Related]

  • 12. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
    Arjomand H, Cohen M, Ezekowitz MD.
    J Invasive Cardiol; 2004 May 26; 16(5):271-8. PubMed ID: 15152137
    [Abstract] [Full Text] [Related]

  • 13. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL.
    J Am Coll Cardiol; 2005 Jan 04; 45(1):1-9. PubMed ID: 15629364
    [Abstract] [Full Text] [Related]

  • 14. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
    Connolly SJ.
    Am Heart J; 2003 Mar 04; 145(3):418-23. PubMed ID: 12660663
    [Abstract] [Full Text] [Related]

  • 15. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL.
    Rev Cardiovasc Med; 2004 Mar 04; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S, Diamond GA, Weintraub WS.
    J Am Coll Cardiol; 2005 Dec 06; 46(11):1986-95. PubMed ID: 16325029
    [Abstract] [Full Text] [Related]

  • 18. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.
    Am J Geriatr Pharmacother; 2009 Jun 06; 7(3):159-66. PubMed ID: 19616184
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 106.